A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients - Scagliotti, Giorgio V.; Moro-Sibilot, Denis; Kollmeier, Jens; Favaretto, Adolfo; Cho, Eun Kyung; Grosch, Heidrun; Kimmich, Martin; Girard, Nicolas; Tsai, Chun-Ming; Hsia, Te-Chun; Brighenti, Matteo; Schumann, Christian; et al. (Journal of thoracic oncology, 2020)
Available online - 14 October 2019